The DENGVAC Study: Preliminary Findings on the Immunogenicity of the TAK-003 Dengue Vaccine - PubMed
11 hours ago
- #dengue vaccine
- #T-cell response
- #immunogenicity
- The DENGVAC study assessed the safety and immunogenicity of the first dose of the TAK-003 dengue vaccine.
- Participants were stratified into three groups: dengue seronegative (Group1), dengue seropositive (Group2), and acute dengue infection (Group3).
- Anti-DENV-2 neutralizing antibodies increased significantly in all groups, with the highest fold increase in Group1 (26.9-fold).
- Group1 showed increased monocytes, while Group3 had reduced myeloid-DC and higher plasmacytoid-DC.
- Group1 and Group2 exhibited DENV CD4 MP-induced T-cell responses similar to Group3, with Group1 showing a greater T-cell response to DENV CD8 MP.
- The TAK-003 vaccine was found to be safe and immunogenic, eliciting functional antibodies and robust T-cell responses.
- Further analyses on the cohort are ongoing to gather more data.